Diagnostic Value of CYFRA 21–1 Tumor Marker and CEA in Pleural Effusion Due to Mesothelioma

Paganuzzi, Michela; Onetto, M.; Marroni, Paola; Filiberti, Rosa Angela; Tassara, E.; Parodi, Stefano; Felletti, Raffaella

doi:10.1378/chest.119.4.1138

Cited by 70 publications

(47 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A large number of studies on the potential diagnostic value of pleural tumor markers have been published, which report either encouraging or disappointing results (Wobbes et al, 1992;Garcia-Pachon et al, 1997;Riantawan et al, 2000;Paganuzzi et al, 2001). The disagreement in results can be attributed to different factors, including the heterogeneity of tumor types, the appropriate inclusion of paramalignant PE to calculate test performances, the sometimes underpowered series, and the use of different methodologies and cut-off values in tumor marker assays (Porcel et al, 2004).…”

Section: Discussionmentioning

confidence: 99%

Application of MMP-7 and MMP-10 in Assisting the Diagnosis of Malignant Pleural Effusion

Cheng

Liang²,

Li³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Application of MMP-7 and MMP-10 in Assisting the Diagnosis of Malignant Pleural Effusion

Cheng

Liang²,

Li³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Because mesothelioma is a rare disease, the use of SMRP as a screening assay may also require the addition of other markers to increase specificity, for example in an asbestos-exposed population. Candidate markers include osteopontin, which was recently reported to be increased in mesothelioma patients (18 ), the absence of increased carcinoembryonic antigen (6 ), or a combination with CYFRA21-1, which could aid in differential diagnosis (19 ). A marker panel requires further studies that are currently ongoing.…”

Section: Discussionmentioning

confidence: 99%

MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma

Beyer

Geschwindt²,

Glover³

et al. 2007

Clinical Chemistry

129

123

View full text Add to dashboard Cite

Background: Soluble mesothelin-related peptides (SMRP) have been reported to be potential biomarkers for malignant pleural mesothelioma (MPM). We report analytical and preliminary clinical studies of MESOMARK TM , a quantitative assay for SMRP. Methods: The MESOMARK assay is a 2-step immunoenzymatic assay in an ELISA format with a 6-point calibration curve (0 -32 nmol/L). We assessed analytical imprecision, analyte stability, and analytical interferences. We measured SMRP by this assay in 409 apparently healthy individuals (reference interval study), 177 patients with nonmalignant conditions, and 500 cancer patients, including 88 with MPM. Results: The limit of detection was 0.16 nmol/L. At 2-19 nmol/L, intraassay imprecision (CV) was 1.1%-5.3%, and total imprecision was 4.0%-11.0%. The mean dilution recovery for 5 samples was 109% (range, 99%-113%). No interference was seen from added bilirubin (200 mg/L), hemoglobin (500 mg/L), triglycerides (30 g/L), chemotherapeutic agents, or other tested substances. Recombinant mesothelin was stable in serum upon freeze/thaw at ؊70°C and upon storage for at least 7 days at 2-8°C. The 99 th percentile of the reference group was 1.5 nmol/L [95% confidence interval (CI), 1.2-1.6 nmol/L; n ‫؍‬ 409], and mean SMRP was significantly higher in sera from patients with MPM (7.5 nmol/L; 95% CI, 2.8 -12.1 nmol/L; n ‫؍‬ 88). SMRP was increased in 52% and 5% of MPM patients and asbestosexposed individuals, respectively. Concentrations in other nonmalignant and malignant conditions were similar to those in healthy controls.

show abstract

“…Various cytokeratins fragments (CYFRA 21.1, tissue polypeptide antigen -TPA) and other cancer antigens (CA 15.3, CA 125 or CA 19.9) have been studied as an aid in the diagnosis of mesothelioma [19,[24][25][26][27][28][29]. Cyfra 21.1 has been shown to be useful in some studies to diagnose malignant pleural effusions [24] but no definitive cut-off value has been established.…”

Section: "Old" Candidate Markersmentioning

confidence: 99%

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Grigoriu

Grigoriu²,

Chahine

et al. 2016

Monaldi Arch Chest Dis

View full text Add to dashboard Cite

Malignant mesothelioma has a very dismal prognosis with very few patients surviving one year after diagnosis. Early multimodal treatment, however, is expected to improve the outcome. Today, there is a strong need to have disease markers which could be used for screening, diagnosing, and/or monitoring tumour response to treatment. Old markers such as hyaluronic acid, various cytokeratin fragments (CYFRA 21.1, TPA) and other cancer antigens (CA 15.3, CA 125 or CA 19.9 or CEA) are not sensitive or specific enough and cannot be used in practice. More recently new molecules, such as soluble mesothelin and osteopontin, have been proposed for diagnostic purposes. Soluble mesothelin has a good specificity but has a suboptimal sensitivity being negative in all sarcomatoid and in up to one half of epithelioid mesothelioma. On the contrary osteopontin has an inadequate specificity. Combining different markers together does not lead to an improvement in diagnostic accuracy. Neither marker can be used for screening purposes, the main limitation being the very low incidence of the disease in the at-risk, asbestos exposed population. Mesothelin is also a promising marker for monitoring response to treatment but published data is still insufficient to make recommendations. There is still a strong need for research is this area both in order to discover new markers as well as to correct the positioning of each existing molecule (alone or in combination) is the evaluation of the patients with a mesothelioma.

show abstract

Diagnostic Value of CYFRA 21–1 Tumor Marker and CEA in Pleural Effusion Due to Mesothelioma

Cited by 70 publications

References 20 publications

Application of MMP-7 and MMP-10 in Assisting the Diagnosis of Malignant Pleural Effusion

Application of MMP-7 and MMP-10 in Assisting the Diagnosis of Malignant Pleural Effusion

MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma

Clinical utility of diagnostic markers for malignant pleural mesothelioma

Contact Info

Product

Resources

About